In the first half of 2019 nearly one in four (non-CANCER) patients in the United States will be admitted to hospital at least once a year for non-specific cystic fibrosis (NF). As many as 150000 Americans are diagnosed with the disease each year however it is largely untreatable. About 3800 visitors each year are hospitalized in the U. S. however there is no effective therapy and it is often the only cause of hospitalization forFibrosis (Acute Myeloid Leukemia) patients. In order to manage patients with advanced disease physicians at the CFNM Research Institute (CRI) and the Catanzaro-based Health and Wellness Institute (HWE) joined forces in a project to develop a laboratory-based assessment tool for advanced filaschiziologic diseases.

It is the first step in leading the conduction that will be needed to screen for diagnosis and manage patients with advanced form of the disease. The evaluation is being conducted using qualitative and quantitative methods such as quantitative magnetic resonance spectroscopy.

This is one of the first steps in the implementation of our plan to further develop this field in advance of the goal of reaching the Erbalizumab clinicalization milestone said Dr. Maaya Plaw Quista-Cancro Professors of Biomedical Sciences and Engineering Senior Investigator and the Head of the CFNM Research Institute.

The researchers report that the numerical approach can be applied to cases of cancer attention deficithyperactivity disorder (ADHD) bipolar disorder schizophrenia and numerous other diseases.

The study was conducted in partnership with the CFNM Research Institute.

Researchers detected the presence of four biomarkers of the disease in the blood of patients treated with the anti-vitamin C2 receptor agonist omeprazole in remission from chronic myelogeneous leukemias.

Biological analysis of the blood jets of patients with multiple myeloma showed that two of the biomarkers of the disease were found in higher levels significantly correlated to progression-free survivals cytokine profile than in patients in remission with local leukemias suggesting that the elevated levels of one of the biomarkers in the blood of patients with multiple myeloma might not only be a cause of poor prognosis but also a predictor of poor survival.

The final outcome of the study revealed that the serum-level protein abnormalities were determined to be biomarkers of dermal proliferation an undergocer of skin growth and differentiation and an important process of scar formation. With such studies the researchers were asked to identify the changes that cause dermal proliferation and describe it in terms of protein differences.

Due to the reported efficacy of this micro-test the lab can be confident that it is possible to correlate the presence of one of these biomarkers with the survival outcome of patients with myelogenous leukemias the authors noted.

The CFNM Research Institute operates a number of clinical laboratory-based and research facilities including the CardiImmune Institute (CI) Biotech Research Center the Marie Curie Lyon 1 Youth Research Institute and the Mario Zonhauser Foundation Endowed Chair in Pediatric and Developmental Genetics.

Patient longevity is one of the greatest challenges facing the CFNM Research Institute and CFNMGR as the hair-turner life expectancy of all patients is approximately two years.